Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 8/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538286 | 0.88 | CCR3 (0.62) | CCR3MAPK8 | |
| SCHEMBL2565277 | 0.77 | CCR3 (0.61) | CCR3 | |
| SCHEMBL2567932 | 0.74 | CCR3 (0.53) | CCR3GPR119SMN1; SMN2 | |
| SCHEMBL22760385 | 0.74 | MAPK8 (0.49) | GPR119MAPK8TP53MEN1KMT2A | |
| SCHEMBL22760106 | 0.74 | MAPK8 (0.49) | GPR119MAPK8ALDH1A1LMNATP53 | |
| SCHEMBL6816823 | 0.72 | SMN1; SMN2 (0.48) | GPR119ALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL2564463 | 0.72 | CCR3 (1.00) | CCR3 | |
| SCHEMBL28812695 | 0.70 | GPR119 (0.54) | GPR119TP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22773305 | 0.69 | CNR1 (0.63) | GPR119TP53SMN1; SMN2 | |
| SCHEMBL29734534 | 0.69 | CNR1 (0.63) | GPR119TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994019-B1 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1994019-B1 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| EP-1994019-A2 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | Boehringer Ingelheim International GmbH (DE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2006117314-A2 | NOVEL PIPERIDIN- SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | CCR3, CCR1, CCR2 | CCR3 1/4885GPR119 98/4885MAPK8 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.